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Abstract 249/250 
Introduction: HIV cohort data from high-income European countries were compared to the UNAIDS 
Spectrum modelling parameters for these same countries to validate mortality rates and excess 
mortality estimates for people living with HIV (PLHIV) on antiretroviral therapy (ART). 
Methods: Data from 2000-2015 were analysed from the Antiretroviral Therapy Cohort Collaboration 
(ART-CC) for Austria, Denmark, France, Italy, the Netherlands, Spain, and Switzerland. Flexible 
parametric models were used to compare All-cause mortality rates in the ART-CC and Spectrum. The 
percentage of AIDS-related deaths and excess mortality (both are the same within Spectrum) were 
compared, with excess mortality defined as that in excess of the general population mortality. 
Results: Analyses included 94026 PLHIV with 585784 person-years of follow-up, from which there 
were 5515 deaths. All-cause annual mortality rates in Spectrum for 2000-2003 were 0.0121, 
reducing to 0.0078 in 2012-2015, whilst the ART-CC's corresponding annual mortality rates were 
0.0151 (95% confidence interval [95%CI]: 0.0130-0.0171) reducing to 0.0049 (95%CI: 0.0039-0.0060). 
The percentage of AIDS-related deaths in Spectrum was 74.7% in 2000-2003, dropping to 43.6% in 
2012-15. In the ART-CC, AIDS-related mortality comprised 45.3% (95%CI: 38.4%-52.9%) of mortality 
in 2000-2003 and 26.7% (95%CI: 19.0%, 46.0%) between 2012-2015. Excess mortality in the ART-CC 
was broadly similar to the Spectrum estimates, dropping from 75.3% (95%CI: 60.3%-95.2%) in 2000-
2003 to 30.7% (95%CI: 25.5%-63.7%) in 2012-2015. 
Conclusions: All-cause mortality assumptions for PLHIV on ART in high-income European settings 
should be adjusted in Spectrum to be higher in 2000-2003 and decline more quickly to levels 
currently captured for recent years. 
Keywords: HIV, AIDS, cause-specific, death, UNAIDS, cohort, duration 
 
  
 4 
 
Introduction 
Mortality rates among people living with HIV (PLHIV) taking antiretroviral therapy (ART) have 
declined since the millennium in high-income European countries[1, 2] because of increasingly 
effective ART regimens that are easy to take and have minimal side effects, as well as other 
improvements in HIV care[3]. Changes to HIV treatment guidelines, which now recommend that 
PLHIV start ART as soon as possible after diagnosis regardless of their CD4 count, will also have 
impacted mortality in recent years[4]. Many studies have shown higher mortality during the first year 
of ART than subsequently[5-7], but this early mortality has declined in recent years because fewer 
PLHIV start ART with severe immunodeficiency[1]. Causes of death among PLHIV on ART have also 
changed, with a smaller proportion of AIDS-related deaths[2]. As the HIV-positive population ages the 
proportion of deaths from causes associated with ageing, such as cancer and cardiovascular disease, 
has increased[2, 8]. 
Spectrum (www.unaids.org/en/dataanalysis/datatools/spectrum-epp) is a comprehensive set of 
models of the HIV epidemics in countries around the world that is used by the United Nations 
Programme on HIV/AIDS (UNAIDS) to produce country-specific estimates of all-cause and AIDS-
related mortality in PLHIV[9]. Spectrum model outputs are used by governments, researchers, and 
policy-makers globally, so it is important that they are as accurate as possible. To test the accuracy 
of the Spectrum mortality estimates, UNAIDS sought to compare methods, parameters and outputs 
of the Spectrum models with those of observational HIV cohorts with good cause of death 
classifications. 
We used data from the Antiretroviral Therapy Cohort Collaboration (ART-CC)[10] of clinical HIV 
cohorts in seven high-income European countries to validate Spectrum model parameters and 
outputs. Analyses compared excess mortality estimates for PLHIV on ART in ART-CC with those from 
Spectrum. The secondary aims were to: 1) investigate the association between duration of ART and 
mortality; 2) compare mortality rates by calendar period in the ART-CC with trends estimated using 
Spectrum; 3) compare the proportion of deaths on ART that are due to AIDS in the ART-CC with 
Spectrum; and 4) provide updated mortality rates to parameterise Spectrum for high-income 
European countries and enable more accurate estimates of excess deaths due to AIDS. 
 
Methods 
ART-CC data 
The ART-CC combines data from HIV cohorts in Europe and North America. Eligible patients are HIV-
1 positive, aged ≥16 years, and started ART on ≥3 drugs without having previously taken 
antiretrovirals. All contributing cohorts have been approved to use their data for research by 
institutional review boards or ethics committees. The cohorts use standardized methods of data 
collection, with follow-up visits scheduled at least every six months. The dataset is described in 
detail elsewhere (www.bristol.ac.uk/art-cc/)[10]. Only European ART-CC cohorts were included in this 
study as the North American cohorts within NA-ACCORD are more representative of the US and 
Canadian populations of PLHIV than those in the ART-CC[11]. The European cohorts included in this 
study were those representative of national populations of PLHIV in their countries due to their 
nationwide geographical coverage and because they contain a high percentage of the PLHIV on ART 
in that country, eg. AHIVCOS contains over 85% of Austria’s PLHIV on ART[12]. The countries and 
cohorts analysed were Austria (AHIVCOS), Denmark (DHK), France (ANRS C03 Aquitaine cohort, 
ANRS CO4 French Hospital Database on HIV FHDH), Italy (ICONA), Netherlands (ATHENA), Spain (Co-
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RIS, PISCIS, VACH), and Switzerland (SHCS). The ART-CC 2015 data update was used (ART-CC receives 
data from its cohorts in cycles, for example the previous update was in 2013). The latest ART start 
date in this analysis was 9th January 2015 and the latest follow-up date used was 31st December 
2015. 
Follow-up started when PLHIV started ART and ended at the earliest of death, loss to follow-up 
(LTFU), or administrative censoring (a cohort-specific database closing date). If a patient’s last clinical 
observation was more than a year before the cohort-specific database close date and they were not 
known to have died, then they were considered lost to follow up. Alternative definitions of LTFU 
using gaps of no contact of one and half years and two years were investigated. Data on follow-up 
between 2000-2015 were analysed, for comparability with Spectrum.  
Coding causes of death 
Data on causes of death were obtained through either linkage with Vital Statistics agencies and 
hospitals or through active follow-up and physician report, depending on the cohort. An adapted 
version of the Cause of Death (CoDe) project protocol (www.cphiv.dk/CoDe.aspx) was used to 
classify causes of death[13]. When ICD-9 or ICD-10 codes or free-text information were available, 
causes of death were classified by a computer algorithm and a clinician. When either ICD-9 or ICD-10 
codes or free-text information were unavailable, then each death was independently classified by 
two clinicians. Panel discussion was used to resolve disagreements between clinicians and/or the 
algorithm. Deaths were classified as AIDS-related if a serious AIDS defining condition had been 
recorded a year prior to the death, and/or a low CD4 count (<100/μL) was the last recorded CD4 
count prior to death (within a year if on treatment, 18 months if off treatment), and there was a 
diagnosis compatible with AIDS as a cause of death. 
Spectrum data 
European country-specific Spectrum outputs were made available to us by those with access to the 
data for each year from 2000 onwards. The outputs used were the number of PLHIV on ART, the 
number of AIDS deaths among persons on ART, and the number of non-AIDS deaths among persons 
on ART (estimated based on non-AIDS mortality rates published in the 2017 World Population 
Prospects data). Mortality rates in Spectrum’s 2018 round of estimates were based on a 2013 
analysis of Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) data 
following methods used by the International epidemiologic Databases to Evaluate AIDS (IeDEA) 
collaboration to estimate mortality rates of PLHIV on ART in low- and middle-income countries[14]. 
Mortality rate trends in Spectrum for Western Europe were calculated by fitting incidence curves to 
program data on new diagnoses and vital registration data on AIDS deaths. These previous Spectrum 
estimates did not take into account time trends in on-ART mortality. 
This study aimed to compare default assumptions and parameters in Spectrum with available cohort 
data. Therefore, the Spectrum data were generated removing customized adjustments to the 
Spectrum default rates – modifications in the on-ART mortality rates to better match program 
reports of AIDS deaths. Removing these customized adjustments and using the default patterns 
meant the Spectrum outputs presented in this analysis were different from the published UNAIDS 
global estimates for Europe[15]. For comparability with the ART-CC, the annual data were grouped 
into the years 2000-2003, 2004-2007, 2008-2011 and 2012-2015. Using the Spectrum data, all-cause 
mortality rates, AIDS-related mortality rates (calculated as the excess mortality above that of the age 
and sex-matched general population), and the percentage of deaths that were AIDS-related were 
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estimated overall and by country. Annual mortality rates were calculated by dividing the number of 
deaths by the number of PLHIV alive at the midpoint of that year, presented as rates per person. 
LTFU in Spectrum only affects the distribution of ART patients by time on ART as the input to 
Spectrum is the number of PLHIV on ART. High rates of LTFU mean that more people need to start 
ART to match the program reports of numbers on ART. As on-ART mortality is higher in the first year 
of treatment, higher LTFU rates are associated with higher overall ART-related mortality. 
Analyses 
ART-CC data were reshaped to separate each calendar year of follow-up for each individual person. 
Age (grouped as 16-24, 25-34, 35-44, and ≥45 years) was updated for each calendar year of follow-
up for each person. The duration on ART for each person was updated for each calendar year and 
categorised firstly as 0-6, 7-11, and ≥12 months, then secondly as 0-<1, 1-<2, 2-<3, 3-<4, and ≥4 
years, to see which categorisation best fitted the data. Categories were chosen to match those used 
in Spectrum.  
For the analyses on duration of ART using data from the ART-CC, combined European rates of and 
incidence rate ratios (IRRs) for all-cause mortality were estimated using mixed-effects Poisson 
models with cohort as the panel variable. These models were adjusted for calendar year, sex, age, 
injecting drug use (IDU) transmission route, CD4 at ART start (categorised as 0-49, 50-99, 100-199, 
200-249, 250-349, 350-499, and ≥500 cells/μL), and duration of ART (using both sets of duration 
categories described above). There were no missing data for any of these variables. 
For the analyses comparing country-specific mortality rates by calendar year group, the Spectrum 
rates were compared with crude and selected rates from ART-CC. Crude rates were stratified by 
calendar year group, and rates were estimated for a non-IDU male, aged 35-44, with a CD4 count at 
ART start of 100-199 cells/μL, who had been on ART for 1-2 years – referred to henceforth as 
“selected rates”. We used flexible parametric survival models on the odds scale with 1 degree of 
freedom, equivalent to a log-logistic survival model[16]. For all Europe-wide comparisons between the 
ART-CC and Spectrum, the country-specific ART-CC mortality rates were weighted proportional to 
the number of PLHIV in each country in Spectrum’s data. To investigate if mortality rates changed 
differently over calendar year group according to CD4 count at ART start, a Poisson model was fit 
with an interaction term between CD4 cell count group (categorised as above) and calendar year 
group, adjusting for variables as above. 
AIDS-related mortality rates were compared between ART-CC and Spectrum. In Spectrum, AIDS-
related mortality is calculated as any mortality among PLHIV that exceeds that in the age- and sex-
matched general population, with mortality rates taken from the UN Department of Economic and 
Social Affairs (www.un.org/development/desa/en/). In the ART-CC we calculated AIDS-related 
mortality using both cause-specific mortality and excess mortality (for a more direct comparison 
with Spectrum estimates). Flexible parametric models were used, adjusting only for calendar year 
group. Non-AIDS related mortality (including deaths coded as unknown/unclassifiable) was censored 
in these analyses. In sensitivity analyses we used a range of assumptions about the 
unknown/unclassifiable causes of deaths to estimate upper and lower bounds and a middle estimate 
for the proportion of deaths that were AIDS-related. These were that the proportion of AIDS-related 
deaths among those coded as unknown/unclassifiable was: 1) zero; 2) equal to the proportion of 
coded deaths that were AIDS-related (sampling from a binomial distribution) – the middle estimate; 
and 3) one. Coding all unknown/unclassifiable deaths as AIDS-related will overestimate the number 
of AIDS-related deaths because the available information for some of these deaths strongly 
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suggested that they were not from AIDS, although it was not sufficient to identify a classifiable cause 
of death. 
Excess mortality was calculated relative to the UN’s sex and age-matched general population 
mortality rates. The percentage of excess deaths in ART-CC was calculated by dividing the excess 
mortality rate by the overall mortality rate, with Bayesian 95% credibility intervals accounting for 
parameter uncertainty calculated using Winbugs 1.4.3. All other analyses used Stata version 15.1. 
 
Results 
The ART-CC dataset contained 94026 PLHIV: 25534 (27.2%) female and 9357 (10.0%) with IDU 
transmission). During 585784 person-years of follow-up after 2000 there were 5515 deaths. At the 
time of starting ART, median age was 37 years (IQR 31-45), median CD4 count was 252 cells/μL (IQR 
126-377), median HIV-1 viral load was 63160 (IQR 11900-199800) copies/mL and 17127 (18.2%) 
PLHIV had been diagnosed with AIDS. When LTFU was defined as no clinical follow-up a year before 
the administrative censoring date, 20763 (22.1%) PLHIV were considered lost, reducing to 15513 
(16.5%) and 6850 (7.3%) for gaps of 1.5 and 2 years, respectively. 
ART duration 
When duration of ART was categorised as 0-6, 7-11, and ≥12 months, mortality rates were highest 
during the first 0-6 months on ART (figure 1a and supplementary table 1). For a male with non-IDU 
transmission, aged 16-24, and baseline CD4 count 100-199 cells/μL in their first 0-6 months on ART, 
the annual mortality rate in 2000-2003 was 0.017 (95%CI 0.011, 0.022) per-person, declining to 
0.006 (0.004, 0.008) between 2012 and 2015. The adjusted mortality IRRs comparing 7-12 and ≥12 
with 0-6 months ART duration were 0.52 (95%CI 0.47-0.59) and 0.35 (0.33-0.38) respectively. When 
duration was categorised as 0-1, 1-2, 2-3, 3-4, and ≥4 years, mortality rates were highest in the first 
year of ART (figure 1b and supplementary table 1). For a non-IDU male, aged 16-24 years with 
baseline CD4 count 100-199 cells/μL in their first year on ART, the 2000-2003 annual mortality rate 
was 0.013 (0.009, 0.017), declining to 0.005 (0.003, 0.006) in 2012-2015. The adjusted IRRs 
compared with the first year of ART were: 0.52 (95%CI 0.47-0.57) for 1-2 years, 0.49 (0.44-0.54) for 
2-3 years, 0.43 (0.38-0.47) for 3-4 years, and 0.44 (0.41, 0.48) for ≥4 years on ART. 
Calendar year period 
Figure 2 shows crude and selected country-specific comparisons of mortality rates between the ART-
CC and Spectrum estimates, by calendar year period: supplementary table 2 provides further detail. 
For Europe overall and all the countries analysed except Austria and the Netherlands, the ART-CC 
crude mortality rates were higher than the Spectrum estimates in the 2000-03 period but lower by 
2012-2015. This indicates that the Spectrum mortality rates are not declining as quickly as those in 
the ART-CC. France and Switzerland had the lowest mortality rates in ART-CC data, whilst Austria and 
Denmark had the highest. The ART-CC analyses suggested that in some countries declines in 
mortality were less rapid in more recent years: this was not apparent in the Spectrum modelling. 
Mortality rates appeared to decline sooner in France and Switzerland than in the other countries 
analysed. Using cause of death coding, estimated rates of AIDS-related mortality, in ART-CC were 
0.0049 in 2000-03, 0.0028 in 2004-07, 0.0020 in 2008-11, and 0.0007 in 2012-15: much lower than in 
Spectrum (0.0091, 0.0074, 0.0054, and 0.0032 in the same periods). However, estimated excess 
mortality rates in ART-CC were more similar to those in Spectrum 0.0115, 0.0082, 0.0045, and 
0.0021 in the same periods), although excess mortality declined more across calendar periods in 
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ART-CC than in Spectrum. Supplementary table 3 shows that declines in mortality rates over 
calendar years were less pronounced among PLHIV starting ART with higher than lower CD4 counts. 
Causes of death 
Table 1 shows the distribution of specific causes of death in the ART-CC by calendar year period. The 
percentage of deaths in ART-CC that were classified as AIDS-related declined from 36% in 2000-03 to 
27% in 2004-07, 25% in 2008-11, and 13% in 2012-2015. However, the percentage classified as 
unknown increased from 16% in 2000-03 to 19% in 2004-07, 20% in 2008-11, and 39% in 2012-15. 
Supplementary table 4 shows lower and upper bounds, and middle estimate of the percentage of 
AIDS-related deaths, based on different assumptions about the unclassified/unknown deaths. Figure 
3 shows a comparison of the percentage of deaths due to AIDS between Spectrum and the ART-CC. 
Supplementary table 5 gives country-specific estimates and confidence intervals. The estimated 
percentage of AIDS deaths was lower in ART-CC than in the Spectrum estimates for all calendar year 
periods, even after assuming that all unknown/unclassifiable deaths were due to AIDS. For 2000-
2011 the percentage of AIDS deaths was lower in ART-CC than in the Spectrum estimates for each 
country analysed, even after assuming that all unknown/unclassifiable deaths in ART-CC were due to 
AIDS. For 2012-2015 the percentage of AIDS deaths was lower in ART-CC than in the Spectrum 
estimates for each country, but this was no longer the case for Denmark, France, Italy, and the 
Netherlands when assuming all unknown/unclassifiable deaths in ART-CC were AIDS-related. 
Estimated percentage excess mortality in ART-CC (75.3% in 2000-03, 66.4% in 2004-07, 52.4% in 
2008-11, 30.7% in 2012-15) was similar to Spectrum (74.7%, 68.4%, 59.1% and 43.6% in the same 
calendar periods) except for 2012-15. 
 
Discussion 
Overall, mortality rates in Spectrum appeared to have been under-estimated for the early years of 
ART and over-estimated for the later years, compared with the ART-CC data. Mortality rates were 
much higher for PLHIV in the ART-CC during their first 0-6 months or first year on ART than 
afterwards. Higher mortality rates at the beginning of ART are likely due to PLHIV presenting late for 
treatment with compromised immune systems. Correspondingly, the decline in mortality over 
calendar years is less pronounced for PLHIV presenting with higher CD4 counts. In both the ART-CC 
and Spectrum the percentage of deaths due to AIDS decreased over the calendar years. The 
percentage of deaths due to AIDS appeared to be over-estimated in Spectrum because it was higher 
than in the ART-CC, even when assuming all unknown/unclassifiable deaths in the ART-CC were due 
to AIDS. However, the percentage of deaths among PLHIV in the ART-CC that were in excess of the 
general population mortality was broadly similar to that in Spectrum. 
These comparisons between Spectrum and the ART-CC draw attention to how excess mortality is 
estimated among PLHIV on ART in high-income settings. Extra mortality can manifest as deaths due 
to AIDS but can also be due to other causes that more common among PLHIV than in the general 
population such as increased inflammation, hepatitis C virus coinfection, smoking, and IDU[17-21]. 
Comparing mortality rates between Spectrum and the ART-CC indicates that Spectrum’s 
assumptions need to be adjusted to reflect higher mortality rates in 2000-03 and lower rates in more 
recent years. Adjustments should account for mortality rates declining more steeply than currently 
assumed. The decrease in mortality rates observed in the ART-CC occurred earlier in some countries 
than others, possibly due to earlier introduction of guidelines and policies for treating HIV[22]. 
Another explanation could be variation in the demographic characteristics of PLHIV across the 
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countries[8]. Mortality rate decreases observed in ART-CC were not linear, for example the decrease 
for Switzerland appeared to level off over time and so may have reached a steady state with little 
room for further improvement in the survival of PLHIV. The increase in the proportion of deaths in 
the ART-CC coded as unknown/unclassifiable in 2012-2015 compared to earlier years could be due 
to various reasons, one being that for some cohorts these later deaths had not been linked to cause 
of death information at the time of the data update. 
Comparison with literature 
A European multi-cohort study by the D:A:D collaboration, containing some of the same cohorts as 
ART-CC, found the percentage of deaths due to AIDS to be 29% between 1999 and 2011[2]. This is 
lower than the percentage found in the European ART-CC cohorts (43% in 2000-03 dropping to 31% 
in 2008-11), but not too dissimilar and could be explained by differences between the cohorts 
analysed. A Public Health England study found the percentage of deaths due to AIDS to be 58% 
between 1997 and 2012[23], although this study also included PLHIV not on ART, possibly explaining 
the higher percentage. Studies in other high-income countries also found similar percentage of 
deaths due to AIDS, such as 40% in the Australian AHOD cohort between 1999-2004[24], similar to the 
ART-CC’s 43% for 2000-03. The BC-CfE study in Vancouver, Canada, found the percentage of deaths 
due to AIDS to be 73% in 2005, falling to 20% in 2013[25]. The 73% is much higher than the ART-CC’s 
comparative 34% for 2004-2007, possibly due to different patient mix and guidelines. However, BC-
CfE’s 20% figure is almost identical to the ART-CC’s 19% seen between 2012-2015. There is 
considerable evidence that, as shown in this study, mortality is highest during the first year of ART 
and decreases afterwards[5-7]. 
Strengths and limitations 
The HIV cohorts included in this analysis are a good representation of the PLHIV on ART in their 
countries in terms of patient mix and due to large sample sizes[10]. The under-ascertainment of 
deaths in the ART-CC due to LTFU may be a limitation, but registry linkages of deaths have been 
done in most cohorts. A French study from 2000 identified a large underreporting of deaths in FHDH 
itself, 62%, which dropped to 8% once other sources of mortality were accounted for[26]. A previous 
ART-CC analysis from 2012 gives self-reported completeness of death ascertainment by cohort and 
found that cohorts with lower completeness also had lower reported mortality rates[27]. LTFU in the 
ART-CC could be due to PLHIV becoming sicker and not turning up to appointments, conversely, it 
could be due to PLHIV being healthy enough to move to another clinic, cohort, or country[28]. Despite 
the percentage of AIDS-related deaths in the ART-CC being lower than in Spectrum, the cause of 
death coding system in the ART-CC may over-estimate AIDS-related deaths because of the use of 
indirect evidence of AIDS, such as low CD4 counts within the year before death[29]. Additionally, how 
excess mortality is defined can make comparisons of mortality rates between the ART-CC and 
Spectrum difficult. Differences between Spectrum and the ART-CC could be methodological or data-
driven, which is also hard to ascertain. For comparability with Spectrum, important variables were 
not adjusted for, so assumptions were made that the characteristics of PLHIV in the ART-CC and 
Spectrum were similar, which may not be the case. For other analyses some variables, such as 
geographical origin, hepatitis C status, and socio-demographic indicators, were not adjusted for as 
they were unavailable for many PLHIV. 
Implications 
The findings of this study indicate that the assumptions around all-cause mortality for PLHIV on ART 
in high-income European settings should be adjusted in Spectrum. Mortality rates for PLHIV on ART 
 10 
 
were higher in 2000-03 and declined more quickly than captured by Spectrum. Although when 
calculating excess mortality in the ART-CC the mortality rates are broadly similar to those in 
Spectrum, the percentage of deaths due to AIDS among PLHIV in the ART-CC is much lower. These 
lower percentages seen in the ART-CC have also been recorded in other studies in high-income 
countries[2, 24, 25]. With increasingly effective ART, much of the excess mortality among PLHIV is due 
to other factors such as higher levels of smoking, IDU, inflammatory markers, and hepatitis co-
infection than in the general population[19-21]. This possibly indicates excess mortality in Spectrum 
should be broken into two categories: AIDS-related excess mortality, and non-AIDS-related excess 
mortality. Additionally, this study gives further information about the effect of duration of ART on 
mortality rates and cause-specific mortality among PLHIV on ART in high-income European 
countries. These findings are likely generalisable to other high-income settings. The new rates 
reported here in supplementary table 1 (model 1) have been incorporated into Spectrum for the 
2019 round of UNAIDS HIV estimates.  
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Table 1: Distribution of cause-of-death in the ART-CC by calendar year period 
 Calendar year period 
Cause of death 2000-2003 2004-2007 2008-2011 2012-2015 
AIDS 496 (36%) 454 (27%) 429 (25%) 90 (13%) 
Cardiovascular 52 (4%) 94 (6%) 85 (5%) 30 (4%) 
Liver 98 (7%) 111 (7%) 139 (8%) 50 (7%) 
Non-AIDS infection 64 (5%) 107 (6%) 84 (5%) 18 (3%) 
Cancer (non-AIDS or liver) 128 (9%) 218 (13%) 281 (16%) 103 (15%) 
Other 200 (14%) 242 (14%) 219 (13%) 83 (12%) 
Respiratory 14 (1%) 28 (2%) 30 (2%) 26 (4%) 
Substance abuse 47 (3%) 37 (2%) 50 (3%) 10 (1%) 
Unknown/unclassifiable 225 (16%) 331 (19%) 337 (20%) 274 (39%) 
Unnatural 56 (4%) 78 (5%) 70 (4%) 26 (4%) 
Total 1380 (100%) 1700 (100%) 1725 (100%) 710 (100%) 
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Figure 1: ART-CC trends across calendar years in mortality rates by duration of ART for a) 0-6, 7-12 
months, and ≥1 years; and b) 0-1, 1-2, 2-3, 3-4, and ≥4 years 
 
 
*Presented for a male with non-IDU transmission, aged 35-44, with baseline CD4 of 250-349 cells/μL 
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Figure 2: Comparison of ART-CC mortality rates (crude and selected*) against Spectrum model 
inputs 
 
  
  
  
  
*A non-IDU male, aged 35-44, with a CD4 count at ART start of 100-199 cells/μL, who had been on 
ART for 1-2 years. 
 14 
 
 
Figure 3: Comparisons of the percentage of deaths due to AIDS in the ART-CC against Spectrum 
model inputs, for separate European countries 
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